(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 60.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.6%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Bridgebio Pharma's revenue in 2025 is $353,780,000.On average, 22 Wall Street analysts forecast BBIO's revenue for 2025 to be $97,343,002,711, with the lowest BBIO revenue forecast at $86,192,870,791, and the highest BBIO revenue forecast at $114,403,513,926. On average, 21 Wall Street analysts forecast BBIO's revenue for 2026 to be $173,642,203,042, with the lowest BBIO revenue forecast at $109,535,689,309, and the highest BBIO revenue forecast at $250,714,165,713.
In 2027, BBIO is forecast to generate $292,339,269,321 in revenue, with the lowest revenue forecast at $207,740,100,414 and the highest revenue forecast at $363,256,112,505.